

DAFTAR REFERENSI

- Abdel-Aziz, A. A. M. *et al.* (2016) ‘Synthesis and potential antitumor activity of 7-(4-substituted piperazin-1-yl)-4-oxoquinolines based on ciprofloxacin and norfloxacin scaffolds: in silico studies’, *Journal of Enzyme Inhibition and Medicinal Chemistry*, 31(5), pp. 796–809. doi: 10.3109/14756366.2015.1069288.
- Afifah, A., Purwonegoro, T. A. and Peramiarti, I. (2017) ‘RESISTENSI *Klebsiella* sp TERHADAP MEROPENEM DI RSUD PROF. DR. MARGONO SOEKARJO PURWOKERTO’, *Scripta Biologica*, 4(2), p. 135. doi: 10.20884/1.sb.2017.4.2.378.
- Agarwal, A. and Jain, A. (2012) ‘Association between drug resistance & production of biofilm in staphylococci Sir’, (April), pp. 562–564.
- Ahmad, N. *et al.* (2018) *Sherris Medical Microbiology Seventh Edition*. Seventh. Edited by K. J. Ryan. New York: Mc Graw Hill Education.
- Akinpelu, S. *et al.* (2020) ‘Efflux pump activity, biofilm formation and antibiotic resistance profile of *Klebsiella* spp. isolated from clinical samples at Lagos University Teaching Hospital’, *BMC Research Notes*, 13(1), pp. 1–5. doi: 10.1186/s13104-020-05105-2.
- Akter, J., Chowdhury, M.A., A, M. and Al Forkan, M. (2014) ‘Study on prevalence and antibiotic resistance pattern of *Klebsiella*’, *American journal of drug discovery and development*, pp. 73–79.
- Al-Marzooq, F., Mohd Yusof, M. Y. and Tay, S. T. (2014a) ‘Molecular analysis of ciprofloxacin resistance mechanisms in Malaysian ESBL-producing *Klebsiella pneumoniae* isolates and development of mismatch amplification mutation assays (MAMA) for rapid detection of *gyrA* and *parC* mutations’, *BioMed Research International*, 2014. doi: 10.1155/2014/601630.
- Al-Marzooq, F., Mohd Yusof, M. Y. and Tay, S. T. (2014b) ‘Molecular analysis of ciprofloxacin resistance mechanisms in Malaysian ESBL-producing *Klebsiella pneumoniae* isolates and development of mismatch amplification mutation assays (MAMA) for rapid detection of *gyrA* and *parC* mutations’, *BioMed Research International*, 2014. doi: 10.1155/2014/601630.
- Al-Naqshbandi, A. A., Chawsheen, M. A. and Abdulqader, H. H. (2019) ‘Prevalence and antimicrobial susceptibility of bacterial pathogens isolated from urine specimens received in rizgary hospital — Erbil’, *Journal of Infection and Public Health*, 12(3), pp. 330–336. doi: 10.1016/j.jiph.2018.11.005.
- Alarcon, T., Pita, J. and Piddock, L. J. V (1993) ‘High-level quinolone resistance amongst clinical isolates of *Escherichia coli* and *Klebsiella pneumoniae* from Spain’, pp. 605–609.
- Aldred, K. J., Kerns, R. J. and Oshero, N. (2014) ‘Mechanism of Quinolone Action and Resistance’, *Biochemistry including biophysical chemistry & molecular biology*, 53, pp. 1565–1574.
- Alegun, O. *et al.* (2021) ‘Donnan potential across the outer membrane of gram-negative bacteria and its effect on the permeability of antibiotics’, *Antibiotics*,

10(6). doi: 10.3390/antibiotics10060701.

- AlMatar, M. *et al.* (2021) 'Efflux pump inhibitors: new updates', *Pharmacological Reports*, 73(1). doi: 10.1007/s43440-020-00160-9.
- Alvarez-Ortega, C., Olivares, J. and Martínez, J. L. (2013) 'RND multidrug efflux pumps: What are they good for?', *Frontiers in Microbiology*, 4(FEB), pp. 1–11. doi: 10.3389/fmicb.2013.00007.
- Alvi, R. F. *et al.* (2021) 'Transcriptional Response of Multidrug-Resistant *Klebsiella pneumoniae* Clinical Isolates to Ciprofloxacin Stress', *Canadian Journal of Infectious Diseases and Medical Microbiology*, 2021, pp. 3–8. doi: 10.1155/2021/5570963.
- Anderl, J. N., Franklin, M. J. and Stewart, P. S. (2000) 'Role of antibiotic penetration limitation in *Klebsiella pneumoniae* biofilm resistance to ampicillin and ciprofloxacin', *Antimicrobial Agents and Chemotherapy*, 44(7), pp. 1818–1824. doi: 10.1128/AAC.44.7.1818-1824.2000.
- Anderson, V. and Osheroff, N. (2005) 'Type II Topoisomerases as Targets for Quinolone Antibacterials Turning Dr. Jekyll into Mr. Hyde', *Current Pharmaceutical Design*, 7(5), pp. 337–353. doi: 10.2174/1381612013398013.
- Andersson, D. I. and Hughes, D. (2017) 'Selection and Transmission of Antibiotic-Resistant Bacteria', *Microbiology Spectrum*, 5(4), pp. 1–17. doi: 10.1128/microbiolspec.mtbp-0013-2016.
- Andres, P. *et al.* (2013) 'Differential Distribution of Plasmid-Mediated Quinolone Resistance Genes in clinical enterobacteria with unusual phenotypes of quinolone susceptibility from Argentina', *Antimicrobial Agents and Chemotherapy*, 57(6), pp. 2467–2475. doi: 10.1128/AAC.01615-12.
- Andriole, V. T. (2005) 'The Quinolones: Past, Present, and Future', 41(Suppl 2), pp. 113–119.
- Anuar, A. S. S., Yusof, M. Y. M. and Tay, S. T. (2013) 'Prevalence of plasmid-mediated', pp. 1744–1747.
- Appelbaum, P. C. and Hunter, P. A. (2000) 'The fluoroquinolone antibacterials: Past, present and future perspectives', *International Journal of Antimicrobial Agents*, 16(1), pp. 5–15. doi: 10.1016/S0924-8579(00)00192-8.
- Arachchige, J., Sampath, A. and Kothalawala, M. (2021) 'Case report Use of high-dose ciprofloxacin for recurrent biofilm-forming multidrug-resistant *Klebsiella pneumoniae* bacteremia', 11(September), pp. 449–453.
- Ardebili, A. *et al.* (2015) 'Association between mutations in *gyrA* and *parC* genes of *Acinetobacter baumannii* clinical isolates and ciprofloxacin resistance', *Iranian Journal of Basic Medical Sciences*, 18(6), pp. 623–626.
- Arzanlou, M., Chai, W. C. and Venter, H. (2017) 'Intrinsic, adaptive and acquired antimicrobial resistance in Gram-negative bacteria', *Essays in Biochemistry*, 61(1), pp. 49–59. doi: 10.1042/EBC20160063.
- Asadi Karam, M. R., Habibi, M. and Bouzari, S. (2019) 'Urinary tract infection: Pathogenicity, antibiotic resistance and development of effective vaccines against Uropathogenic *Escherichia coli*', *Molecular Immunology*, 108(69), pp. 56–67. doi: 10.1016/j.molimm.2019.02.007.

- Ashley, R. E. *et al.* (2017) 'Activities of gyrase and topoisomerase IV on positively supercoiled DNA', *Nucleic Acids Research*, 45(16), pp. 9611–9624. doi: 10.1093/nar/gkx649.
- Auquer, F. *et al.* (2002) 'Single-dose ciprofloxacin versus 3 days of norfloxacin in uncomplicated urinary tract infections in women', *Clinical Microbiology and Infection*, 8(1), pp. 50–54. doi: 10.1046/j.1198-743x.2001.00359.x.
- Azeredo, J. *et al.* (2017) 'Critical review on biofilm methods', *Critical Reviews in Microbiology*, 43(3), pp. 313–351. doi: 10.1080/1040841X.2016.1208146.
- Baggio, D. and Ananda-Rajah, M. R. (2021) 'Fluoroquinolone antibiotics and adverse events', 44(5), pp. 161–164.
- Bajaj, H. *et al.* (2017) 'Bacterial Outer Membrane Porins as Electrostatic Nanosieves: Exploring Transport Rules of Small Polar Molecules', *ACS Nano*, 11(6), pp. 5465–5473. doi: 10.1021/acsnano.6b08613.
- Baker, K. S. *et al.* (2018) 'Horizontal antimicrobial resistance transfer drives epidemics of multiple *Shigella* species', *Nature Communications*, 9(1), pp. 1–10. doi: 10.1038/s41467-018-03949-8.
- Bakke, R., Kommedal, R. and Kalvenes, S. (2001) 'QUANTIFICATION OF BIOFILM ACCUMULATION BY AN OPTICAL APPROACH R.', *Journal of Microbiological Methods*, 44(1), pp. 13–26.
- Banerjee, T. *et al.* (2018) 'High Prevalence and Endemicity of Multidrug Resistant *Acinetobacter* spp. in Intensive Care Unit of a Tertiary Care Hospital, Varanasi, India', *Journal of Pathogens*, 2018, pp. 1–8. doi: 10.1155/2018/9129083.
- Bassetti, M. *et al.* (2018) 'Multidrug-resistant *Klebsiella pneumoniae*: Challenges for treatment, prevention and infection control', *Expert Review of Anti-Infective Therapy*, 16(10), pp. 749–761. doi: 10.1080/14787210.2018.1522249.
- Baugh, S. *et al.* (2012) 'Loss of or inhibition of all multidrug resistance efflux pumps of *Salmonella enterica* serovar Typhimurium results in impaired ability to form a biofilm', *Journal of Antimicrobial Chemotherapy*, 67(10), pp. 2409–2417. doi: 10.1093/jac/dks228.
- Bengoechea, A. *et al.* (2019) '*Klebsiella pneumoniae* infection biology: living to counteract host defences', (November 2018), pp. 123–144. doi: 10.1093/femsre/fuy043.
- Bharatham, N. *et al.* (2021) 'Structure and function relationship of OqxB efflux pump from *Klebsiella pneumoniae*', *Nature Communications*, 12(1). doi: 10.1038/s41467-021-25679-0.
- Bi, W. *et al.* (2017) 'Extensively drug-resistant *Klebsiella pneumoniae* causing nosocomial bloodstream infections in China: Molecular investigation of antibiotic resistance determinants, Informing therapy, and clinical outcomes', *Frontiers in Microbiology*, 8(JUN). doi: 10.3389/fmicb.2017.01230.
- Blackwell, W. (2020) *Bacterial Resistance to Antibiotic-From Molecules to Man*. First edit. Edited by B. B. Bonev and M. B. Nocholas. USA: John Willey & Sons, Inc.
- Bradley, J. S. *et al.* (2021) *Nelson's Pediatric Antimicrobial Therapy*. 27th Editi.

American: American Academy of Pediatric.

- Brisse, S. *et al.* (2000) 'Epidemiology of Quinolone Resistance of *Klebsiella pneumoniae* and *Klebsiella oxytoca* in Europe', (January 1999), pp. 64–68.
- Brisse, S. *et al.* (2013) 'Wzi gene sequencing, a rapid method for determination of capsulartype for *klebsiella* strains', *Journal of Clinical Microbiology*, 51(12), pp. 4073–4078. doi: 10.1128/JCM.01924-13.
- Brisse, S., Passet, V. and Grimont, P. A. D. (2014) 'Description of *Klebsiella quasipneumoniae* sp. nov., Isolated from human infections, With two subspecies, *Klebsiella quasipneumoniae* subsp. *quasipneumoniae* subsp. nov. and *Klebsiella quasipneumoniae* subsp. *similipneumoniae* subsp. nov., And demonstration th', *International Journal of Systematic and Evolutionary Microbiology*, 64, pp. 3146–3152. doi: 10.1099/ijs.0.062737-0.
- Burillo, A. and Bouza, E. (2014) 'Use of rapid diagnostic techniques in ICU patients with infections', *BMC Infectious Diseases*, 14(1), pp. 1–12. doi: 10.1186/s12879-014-0593-1.
- Burke, L., Humphreys, H. and Fitzgerald-Hughes, D. (2012) 'The revolving door between hospital and community: Extended-spectrum beta-lactamase-producing *Escherichia coli* in Dublin', *Journal of Hospital Infection*, 81(3), pp. 192–198. doi: 10.1016/j.jhin.2012.04.021.
- Cassini, A. *et al.* (2019) 'Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis', *The Lancet Infectious Diseases*, 19(1), pp. 56–66. doi: 10.1016/S1473-3099(18)30605-4.
- Cataldo, M. A. *et al.* (2020) 'Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company ' s public news and information ', (January), pp. 19–21.
- Cepas, V. *et al.* (2019) 'Relationship between Biofilm Formation and Antimicrobial Resistance in Gram-Negative Bacteria', *Microbial Drug Resistance*, 25(1), pp. 72–79. doi: 10.1089/mdr.2018.0027.
- Champoux, J. J. (2001) 'DNA T OPOISOMERASES : Structure , FunctChampoux, J. J. (2001). DNA T OPOISOMERASES : Structure , Function , 369–413.ion ', *Annu. Rev. Biochem.*, 70, pp. 369–413.
- Chanbari, M., Mirnejad, R. and Babapour, E. (2020) 'Evaluation of Resistance to Fluoroquinolones and its Relationship whit parC Gene mutation in *Klebsiella pneumoniae* Clinical Isolates', *Iranian Journal of Medical Microbiology*, 14(3), pp. 270–289. doi: 10.30699/ijmm.14.3.270.
- Chang, D. *et al.* (2021) 'Clinical Epidemiology, Risk Factors, and Control Strategies of *Klebsiella pneumoniae* Infection', *Frontiers in Microbiology*, 12(December), pp. 1–9. doi: 10.3389/fmicb.2021.750662.
- Channar, P. A. *et al.* (2017) 'Sulfonamide-Linked ciprofloxacin, sulfadiazine and amantadine derivatives as a novel class of inhibitors of jack bean urease; synthesis, kinetic mechanism and molecular docking', *Molecules*, 22(8), pp. 1–20. doi: 10.3390/molecules22081352.

- Chen, W. *et al.* (2016) 'Effects of *Scutellaria Baicalensis* on Activity and Biofilm Formation of *Klebsiella Pneumoniae*', *Chinese Medical Sciences Journal*, 31(3), pp. 180–184. doi: 10.1016/S1001-9294(16)30048-7.
- Cheng, J. *et al.* (2020) 'Correction to: Time to positivity of *Klebsiella pneumoniae* in blood culture as prognostic indicator for pediatric bloodstream infections (European Journal of Pediatrics, (2020), 179, 11, (1689-1698), 10.1007/s00431-020-03675-8)', *European Journal of Pediatrics*, 179(11), p. 1699. doi: 10.1007/s00431-020-03707-3.
- Cherif-Antar, A. *et al.* (2016) 'Diversity and biofilm-forming capability of bacteria recovered from stainless steel pipes of a milk-processing dairy plant', *Dairy Science and Technology*, 96(1), pp. 27–38. doi: 10.1007/s13594-015-0235-4.
- Chevalier, J. *et al.* (2000) 'Membrane permeability modifications are involved in antibiotic resistance in *Klebsiella pneumoniae*', *Biochemical and Biophysical Research Communications*, 274(2), pp. 496–499. doi: 10.1006/bbrc.2000.3159.
- Cholley, P. *et al.* (2013) 'Hospital cross-transmission of extended-spectrum β -lactamase producing *Escherichia coli* and *Klebsiella pneumoniae*', *Medecine et Maladies Infectieuses*, 43(8), pp. 331–336. doi: 10.1016/j.medmal.2013.06.001.
- Christaki, E., Marcou, M. and Tofarides, A. (2019) 'Antimicrobial Resistance in Bacteria : Mechanisms , Evolution , and Persistence', *Journal of Molecular Evolution*, (0123456789). doi: 10.1007/s00239-019-09914-3.
- Chu, L. *et al.* (2022) 'Efficacy and Safety of Ciprofloxacin Plus Fluocinolone Acetonide Among Patients With Acute Otitis Externa: A Randomized Clinical Trial', *JAMA Network Open*, 5(7), p. E2221699. doi: 10.1001/jamanetworkopen.2022.21699.
- Chung, P. Y. (2016) 'The emerging problems of *Klebsiella pneumoniae* infections: Carbapenem resistance and biofilm formation', *FEMS Microbiology Letters*, 363(20), pp. 1–6. doi: 10.1093/femsle/fnw219.
- Coculescu, B. I. (2009) 'Antimicrobial resistance induced by genetic changes.', *Journal of medicine and life*, 2(2), pp. 114–123.
- Conlan, S. *et al.* (2015) 'NIH Public Access', 6(254). doi: 10.1126/scitranslmed.3009845.Single.
- Custovic, A. *et al.* (2014) 'Epidemiological Surveillance of Bacterial Nosocomial Infections in the Surgical Intensive Care Unit', *Materia Socio Medica*, 26(1), p. 7. doi: 10.5455/msm.2014.26.7-11.
- Dehnamaki, M., Ghane, M. and Babaeekhou, L. (2020) 'Detection of OqxAB and QepA Efflux Pumps and Their Association with Antibiotic Resistance in *Klebsiella pneumoniae* Isolated From Urinary Tract Infection', *International Journal of Infection*, 7(4). doi: 10.5812/iji.107397.
- Derivatives, I., Cernicchi, G. and Felicetti, T. (2021) 'Microbial Efflux Pump Inhibitors : A Journey around Quinoline'.
- Doménech-Sánchez, A. *et al.* (2000) 'Activity of nine antimicrobial agents against clinical isolates of *Klebsiella pneumoniae* producing extended-spectrum β -lactamases and deficient or not in porins [9]', *Journal of Antimicrobial*

Chemotherapy, 46(5), pp. 858–860. doi: 10.1093/jac/46.5.858.

- Dunstan, R. A. *et al.* (2021) ‘Mechanistic Insights into the Capsule-Targeting Depolymerase from a *Klebsiella pneumoniae* Bacteriophage’, *Microbiology Spectrum*, 9(1), pp. 1–15. doi: 10.1128/spectrum.01023-21.
- Edwardson, S. and Cairns, C. (2019) ‘Nosocomial infections in the ICU’, *Anaesthesia and Intensive Care Medicine*, 20(1), pp. 14–18. doi: 10.1016/j.mpaic.2018.11.004.
- Efendi, N. Y. and Hertiani, T. (2013) ‘Antimicrobial Potency of Ant-Plant Extract (*Myrmecodia Tuberosa* Jack.) Against *Candida Albicans*, *Escherichia Coli*, and *Staphylococcus Aureus* Potensi Antimikroba Ekstrak Etanol Sarang Semut (*Myrmecodiatuberosa* Jack.) Terhadap *Candida Albicans*, *Escherichia*’, *Traditional Medicine Journal*, 18(1), p. 2013.
- Elgendy, S. G., Hameed, M. R. A. and El-mokhtar, M. A. (2018) ‘Tigecycline resistance among *Klebsiella pneumoniae* isolated from febrile neutropenic patients’, *Journal of Medical Microbiology*, 67, pp. 972–975. doi: 10.1099/jmm.0.000770.
- Emmerson, A. M. and Jones, A. M. (2003) ‘The quinolones: Decades of development and use’, *Journal of Antimicrobial Chemotherapy*, 51(SUPPL. 1), pp. 13–20. doi: 10.1093/jac/dkg208.
- Eyler, R. F. and Shvets, K. (2019) ‘Clinical pharmacology of antibiotics’, *Clinical Journal of the American Society of Nephrology*, 14(7), pp. 1080–1090. doi: 10.2215/CJN.08140718.
- Favour, O. *et al.* (2014) ‘*Klebsiella* has taken lead among uropathogens in University of Benin Teaching Hospital, Benin City, Nigeria-An observation’, *New York Science Journal*, 3(11), pp. 61–64.
- Fida, M. *et al.* (2021) ‘Detection of Pathogenic Bacteria from Septic Patients Using 16S rRNA gene Targeted Metagenomic Sequencing Accepted’, *Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com*, pp. 1–18.
- Fontana, C. *et al.* (2021) ‘Co-infections observed in SARS-CoV-2 positive patients using a rapid diagnostic test’, *Scientific Reports*, 11(1), pp. 1–10. doi: 10.1038/s41598-021-95772-3.
- Forterre, P. and Gadelle, D. (2009) ‘Phylogenomics of DNA topoisomerases: Their origin and putative roles in the emergence of modern organisms’, *Nucleic Acids Research*, 37(3), pp. 679–692. doi: 10.1093/nar/gkp032.
- Freedberg, D. E. *et al.* (2018) ‘Pathogen colonization of the gastrointestinal microbiome at intensive care unit admission and risk for subsequent death or infection’, *Intensive Care Medicine*, 44(8), pp. 1203–1211. doi: 10.1007/s00134-018-5268-8.
- Fu, Y. *et al.* (2008) ‘Alteration of GyrA amino acid required for ciprofloxacin resistance in *Klebsiella pneumoniae* isolates in China’, *Antimicrobial Agents and Chemotherapy*, 52(8), pp. 2980–2983. doi: 10.1128/AAC.00151-08.
- Garrity, G., Bell, J. and Lilburn, T. (2010) ‘Family I. Pseudomonadaceae’, *Bergey’s Manual of Systematic Bacteriology*, vol 2B, pp. 323–379.

- Garvey, M. I. *et al.* (2011) 'Overexpression of patA and patB, which encode ABC transporters, is associated with fluoroquinolone resistance in clinical isolates of *Streptococcus pneumoniae*', *Antimicrobial Agents and Chemotherapy*, 55(1), pp. 190–196. doi: 10.1128/AAC.00672-10.
- Geetha, V. P. *et al.* (2020) 'Fluoroquinolone Resistance in Clinical Isolates of *Klebsiella Pneumoniae*', *Journal of Laboratory Physicians*, 12(2), pp. 121–125.
- Geng, S. *et al.* (2021) 'Metagenomic next-generation sequencing technology for detection of pathogens in blood of critically ill patients', *International Journal of Infectious Diseases*, 103, pp. 81–87. doi: 10.1016/j.ijid.2020.11.166.
- Grillon, A. *et al.* (2016) 'Comparative activity of ciprofloxacin, levofloxacin and moxifloxacin against *Klebsiella pneumoniae*, *Pseudomonas aeruginosa* and *Stenotrophomonas maltophilia* assessed by minimum inhibitory concentrations and time-kill studies', *PLoS ONE*, 11(6), pp. 1–10. doi: 10.1371/journal.pone.0156690.
- Gupta, R. *et al.* (2017) 'Epidemiology of multidrug-resistant Gram-negative pathogens isolated from ventilator-associated pneumonia in ICU patients', *Journal of Global Antimicrobial Resistance*, 9, pp. 47–50. doi: 10.1016/j.jgar.2016.12.016.
- Hamdan, H. Z. *et al.* (2015) 'Urinary tract infections and antimicrobial sensitivity among diabetic patients at Khartoum, Sudan', *Annals of Clinical Microbiology and Antimicrobials*, 14(1), pp. 1–6. doi: 10.1186/s12941-015-0082-4.
- Hamzaoui, Z. *et al.* (2018) 'An outbreak of NDM-1-producing *klebsiella pneumoniae*, associated with OmpK35 and OmpK36 porin loss in Tunisia', *Microbial Drug Resistance*, 24(8), pp. 1137–1147. doi: 10.1089/mdr.2017.0165.
- Handal, R. *et al.* (2017) 'Characterization of Carbapenem-Resistant *Acinetobacter baumannii* Strains Isolated from Hospitalized Patients in Palestine', *International Journal of Microbiology*, 2017(2006). doi: 10.1155/2017/8012104.
- Haque, M. (2017) 'Antimicrobial use, prescribing, and resistance in selected ten selected developing countries: A brief overview', *Asian Journal of Pharmaceutical and Clinical Research*, 10(8), pp. 37–45. doi: 10.22159/ajpcr.2017.v10i8.19468.
- Hasan, T. H. *et al.* (2021) 'The Epidemiology of *Klebsiella Pneumoniae*: A Review Epidemiology: Human beings represent *K. pneumoniae* as the main reservoir (Kadhum & Hasan, 2019).', 25(4), pp. 8848–8860.
- Hasani, Alka *et al.* (2020) 'Serotyping of *klebsiella pneumoniae* and its relation with capsule-associated virulence genes, antimicrobial resistance pattern, and clinical infections: A descriptive study in medical practice', *Infection and Drug Resistance*, 13, pp. 1971–1980. doi: 10.2147/IDR.S243984.
- Hassan, A. *et al.* (2011a) 'Evaluation of different detection methods of biofilm formation in the clinical isolates', *Brazilian Journal of Infectious Diseases*,

15(4), pp. 305–311. doi: 10.1590/S1413-86702011000400002.

- Hassan, A. *et al.* (2011b) 'Evaluation of different detection methods of biofilm formation in the clinical isolates', *The Brazilian Journal of Infectious Diseases*, 15(4), pp. 305–311. doi: 10.1016/s1413-8670(11)70197-0.
- Haverkate, M. R. *et al.* (2015) 'Within-host and population transmission of blaOXA-48 in *K. pneumoniae* and *E. coli*', *PLoS ONE*, 10(10), pp. 4–6. doi: 10.1371/journal.pone.0140960.
- Henderson, J. C. *et al.* (2016) 'The Power of Asymmetry: Architecture and Assembly of the Gram-Negative Outer Membrane Lipid Bilayer', *Annual Review of Microbiology*, 70(June), pp. 255–278. doi: 10.1146/annurev-micro-102215-095308.
- Hendrik, T. C., Voor, A. F. and Vos, M. C. (2015) 'Clinical and Molecular Epidemiology of Producing *Klebsiella* spp.: A Systematic Review and Meta-Analyses', pp. 1–23. doi: 10.1371/journal.pone.0140754.
- Herbert, D. A. (2014) 'Successful Oral Ciprofloxacin Therapy of *Neisseria elongata* Endocarditis', *Annals of Pharmacotherapy*, 48(11), pp. 1529–1530. doi: 10.1177/1060028014545355.
- Herridge, W. P. *et al.* (2020) 'Bacteriophages of *Klebsiella* spp., their diversity and potential therapeutic uses', *Journal of Medical Microbiology*, 69(2), pp. 176–194. doi: 10.1099/jmm.0.001141.
- Holmes, A. H. *et al.* (2016) 'Understanding the mechanisms and drivers of antimicrobial resistance', *The Lancet*, 387(10014), pp. 176–187. doi: 10.1016/S0140-6736(15)00473-0.
- Holt, K. E. *et al.* (2015) 'Genomic analysis of diversity, population structure, virulence, and antimicrobial resistance in *Klebsiella pneumoniae*, an urgent threat to public health', *Proceedings of the National Academy of Sciences of the United States of America*, 112(27), pp. E3574–E3581. doi: 10.1073/pnas.1501049112.
- Hooper, D. C. and Jacoby, G. A. (2015) 'Mechanisms of drug resistance: Quinolone resistance', *Annals of the New York Academy of Sciences*, 1354(1), pp. 12–31. doi: 10.1111/nyas.12830.
- Horii, T., Osaki, M. and Muramatsu, H. (2008) 'Fluoroquinolone resistance in clinical isolates of *Klebsiella oxytoca*', *Chemotherapy*, 54(4), pp. 323–327. doi: 10.1159/000151266.
- Hsieh, P. F. *et al.* (2016) 'The *Klebsiella pneumoniae* YfgL (BamB) lipoprotein contributes to outer membrane protein biogenesis, type-1 fimbriae expression, anti-phagocytosis, and in vivo virulence', *Virulence*, 7(5), pp. 587–601. doi: 10.1080/21505594.2016.1171435.
- Hu, Y. *et al.* (2020) 'Prevalence, risk factors and molecular epidemiology of carbapenem-resistant *Klebsiella pneumoniae* in patients from Zhejiang, China, 2008–2018', *Emerging Microbes and Infections*, pp. 1771–1779. doi: 10.1080/22221751.2020.1799721.
- Hu, Y. Q., Zhang, S., *et al.* (2017) '4-Quinolone hybrids and their antibacterial activities', *European Journal of Medicinal Chemistry*, 141, pp. 335–345. doi: 10.1016/j.ejmech.2017.09.050.

- Hu, Y. Q., Gao, C., *et al.* (2017) 'Quinoline hybrids and their antiplasmodial and antimalarial activities', *European Journal of Medicinal Chemistry*, 139, pp. 22–47. doi: 10.1016/j.ejmech.2017.07.061.
- Huang, Y. *et al.* (2015) 'Comparative analysis of quinolone resistance in clinical isolates of *Klebsiella pneumoniae* and *Escherichia coli* from Chinese children and adults', *BioMed Research International*, 2015. doi: 10.1155/2015/168292.
- Iredell, J., Brown, J. and Tagg, K. (2016) 'Antibiotic resistance in Enterobacteriaceae: Mechanisms and clinical implications', *BMJ (Online)*, 352. doi: 10.1136/bmj.h6420.
- Jamal, M. *et al.* (2018) 'Bacterial biofilm and associated infections', *Journal of the Chinese Medical Association*, 81(1), pp. 7–11. doi: 10.1016/j.jcma.2017.07.012.
- Jazeela, K. *et al.* (2019) 'Comparison of Mismatch Amplification Mutation Assay PCR and PCR-Restriction Fragment Length Polymorphism for Detection of Major Mutations in *gyrA* and *parC* of *Escherichia coli* Associated with Fluoroquinolone Resistance', *Microbial Drug Resistance*, 25(1), pp. 23–31. doi: 10.1089/mdr.2017.0351.
- Jiang, S. *et al.* (2018) 'Drug Resistance and Gene Transfer Mechanisms in Respiratory/Oral Bacteria', *Journal of Dental Research*, 97(10), pp. 1092–1099. doi: 10.1177/0022034518782659.
- Kareem, S. M. *et al.* (2021) 'Detection of *gyrA* and *parC* Mutations and Prevalence of Plasmid-Mediated Quinolone Resistance Genes in *Klebsiella pneumoniae*', pp. 555–563.
- Kashefieh, M. *et al.* (2021) 'The Molecular Epidemiology of Resistance to Antibiotics among *Klebsiella pneumoniae* Isolates in Azerbaijan, Iran', *Journal of Tropical Medicine*, 2021. doi: 10.1155/2021/9195184.
- Kaur, A. *et al.* (2022) 'Antibiotic resistance pattern of *Klebsiella pneumoniae* a major problem for society', *International journal of health sciences*, 6(April), pp. 4699–4712. doi: 10.53730/ijhs.v6ns2.6124.
- Kazanjian, P. (2017) *History of antimicrobial stewardship*, *Antimicrobial stewardship: principles and practice*. doi: 10.1079/9781780644394.0015.
- Kementerian Kesehatan Republik Indonesia (2017) *Keputusan Menteri Kesehatan Republik Indonesia, Nomor HK.01.07/MENKES/342/2017 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Sepsis*.
- Khalid, T. W. B. M. and Ghaima, K. K. (2022) 'Effect the Natural Efflux Pump Inhibitor (Berberine) in Multidrug Resistant *Klebsiella pneumoniae* Isolated from Urinary Tract Infections in Several Baghdad Hospitals', *Egyptian Journal of Hospital Medicine*, 89(2), pp. 6882–6888. doi: 10.21608/ejhm.2022.271906.
- Khodadadian, R. *et al.* (2018) 'Detection of VIM-1 and IMP-1 genes in *Klebsiella pneumoniae* and relationship with biofilm formation', *Microbial Pathogenesis*, 115(November 2017), pp. 25–30. doi: 10.1016/j.micpath.2017.12.036.
- Khoshnood, S. *et al.* (2020) 'Involvement of the AcrAB Efflux Pump in

- Ciprofloxacin Resistance in Clinical *Klebsiella Pneumoniae* Isolates', *Infectious Disorders - Drug Targets*, 21(4), pp. 564–571. doi: 10.2174/1871526520999200905121220.
- Kim, T. H. *et al.* (2020) 'Novel cassette assay to quantify the outer membrane permeability of five β -lactams simultaneously in carbapenem-resistant *klebsiella pneumoniae* and *enterobacter cloacae*', *American Society for Microbiology mBio*, 11(1), pp. 1–15.
- Kochan, T. J. *et al.* (2022) 'Genomic surveillance for multidrug-resistant or hypervirulent *Klebsiella pneumoniae* among United States bloodstream isolates', *BMC Infectious Diseases*, 22(1), pp. 1–21. doi: 10.1186/s12879-022-07558-1.
- Kong, K. F., Vuong, C. and Otto, M. (2006) 'Staphylococcus quorum sensing in biofilm formation and infection', *International Journal of Medical Microbiology*, 296(2–3), pp. 133–139. doi: 10.1016/j.ijmm.2006.01.042.
- Kowalska-Krochmal, B. and Dudek-Wicher, R. (2021) 'The minimum inhibitory concentration of antibiotics: Methods, interpretation, clinical relevance', *Pathogens*, 10(2), pp. 1–21. doi: 10.3390/pathogens10020165.
- Kumar, A. *et al.* (2010) 'A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: A meta-analytic/meta-regression study', *Critical Care Medicine*, 38(8), pp. 1651–1664. doi: 10.1097/CCM.0b013e3181e96b91.
- Kumar, V. and Park, S. (2018) 'Potential and limitations of *Klebsiella pneumoniae* as a microbial cell factory utilizing glycerol as the carbon source', *Biotechnology Advances*, 36(1), pp. 150–167. doi: 10.1016/j.biotechadv.2017.10.004.
- Laudy, A. E., Kulińska, E. and Tyski, S. (2017) 'The impact of efflux pump inhibitors on the activity of selected non-antibiotic medicinal products against gram-negative bacteria', *Molecules*, 22(1), pp. 1–12. doi: 10.3390/molecules22010114.
- Leboffe, M. J. and Pierce, B. E. (2011) *A Photographic Atlas Microbiology Laboratory*. 4 th Editi, *Morton Pbulishing*. 4 th Editi. United States of America. doi: 10.2174/187152008785133128.
- Lee, J. H. (2019) 'Perspectives towards antibiotic resistance: from molecules to population', *Journal of Microbiology*, 57(3), pp. 181–184. doi: 10.1007/s12275-019-0718-8.
- Lequette, Y. and Greenberg, E. P. (2005) 'Timing and localization of rhamnolipid synthesis gene expression in *Pseudomonas aeruginosa* biofilms', *Journal of Bacteriology*, 187(1), pp. 37–44. doi: 10.1128/JB.187.1.37-44.2005.
- Lerminiaux, N. A. and Cameron, A. D. S. (2019) 'Horizontal transfer of antibiotic resistance genes in clinical environments', *Canadian Journal of Microbiology*, 65(1), pp. 34–44. doi: 10.1139/cjm-2018-0275.
- Li, B. *et al.* (2012) 'Analysis of drug resistance determinants in *Klebsiella pneumoniae* isolates from a tertiary-care hospital in Beijing, China', *PLoS ONE*, 7(7). doi: 10.1371/journal.pone.0042280.
- Li, Z. *et al.* (1998) 'Alteration in the GyrA subunit of DNA gyrase and the ParC

subunit of DNA topoisomerase IV in quinolone-resistant clinical isolates of *Staphylococcus epidermidis*', *Antimicrobial Agents and Chemotherapy*, 42(12), pp. 3293–3295. doi: 10.1128/aac.42.12.3293.

- Liao, C. H. *et al.* (2013) 'Risk factors and clinical characteristics of patients with qnr-positive *Klebsiella pneumoniae* bacteraemia', *Journal of Antimicrobial Chemotherapy*, 68(12), pp. 2907–2914. doi: 10.1093/jac/dkt295.
- Litwin, A., Fedorowicz, O. and Duszynska, W. (2020) 'Characteristics of microbial factors of healthcare-associated infections including multidrug-resistant pathogens and antibiotic consumption at the university intensive care unit in Poland in the years 2011–2018', *International Journal of Environmental Research and Public Health*, 17(19), pp. 1–14. doi: 10.3390/ijerph17196943.
- Livak, K. J. and Schmittgen, T. D. (2001) 'Analysis of relative gene expression data using real-time quantitative PCR and the 2- $\Delta\Delta$ CT method', *Methods*, 25(4), pp. 402–408. doi: 10.1006/meth.2001.1262.
- Livnmore, D. M. and Yuan, M. (1996) 'Antibiotic resistance and production of extended-spectrum β -lactamases amongst *Klebsiella* spp. from intensive care units in Europe *Klebsiellae* account for 10-20 % of opportunistic Gram-negative pathogens from in-patients (Chen *et al.* , 1993). Their suc', pp. 409–424.
- M100–S25, C. D. (2015) *Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: 25th Informational Supplement*; Clinical and Laboratory Standards Institute. Wayne, PA, USA; Clinical and Laboratory Standards Institute. doi: 10.1108/08876049410065598.
- Machado, D. *et al.* (2017) 'Mode of action of the 2-phenylquinoline efflux inhibitor PQQ4R against *Escherichia coli*', *PeerJ*, 2017(4). doi: 10.7717/peerj.3168.
- Mah, T. (2012) 'Biofilm-specific antibiotic resistance', pp. 1061–1072.
- Mah, T. F. C. and O'Toole, G. A. (2001) 'Mechanisms of biofilm resistance to antimicrobial agents', *Trends in Microbiology*, 9(1), pp. 34–39. doi: 10.1016/S0966-842X(00)01913-2.
- Mahapatra, A. *et al.* (2022) 'Ciprofloxacin-resistant Gram-negative isolates from a tertiary care hospital in Eastern India with novel *gyrA* and *parC* gene mutations', *Medical Journal Armed Forces India*, 78(1), pp. 24–31. doi: 10.1016/j.mjafi.2019.10.002.
- Malekshahi, S. S. *et al.* (2021) 'Prevalence of Human Metapneumovirus Infections in Iran: A Systematic Review and Meta-Analysis', *Fetal and Pediatric Pathology*, 40(6), pp. 663–673. doi: 10.1080/15513815.2020.1725939.
- Martin, Rebekah M. and Bachman, M. A. (2018) 'Colonization, infection, and the accessory genome of *Klebsiella pneumoniae*', *Frontiers in Cellular and Infection Microbiology*, 8(JAN), pp. 1–15. doi: 10.3389/fcimb.2018.00004.
- Martin, Rebekah M and Bachman, M. A. (2018) 'Colonization , Infection , and the Accessory Genome of *Klebsiella pneumoniae*', 8(January), pp. 1–15. doi: 10.3389/fcimb.2018.00004.
- Martins, M. *et al.* (2010) 'in Bacterial Clinical Isolates by Two Simple Methods', 642, pp. 143–157. doi: 10.1007/978-1-60327-279-7.

- Martins, M. *et al.* (2013) 'A Simple Method for Assessment of MDR Bacteria for Over-Expressed Efflux Pumps', *The Open Microbiology Journal*, 7(1), pp. 72–82. doi: 10.2174/1874285801307010072.
- Masturoh, I. and Anggita, N. T. (2018) *Metodologi Penelitian Kesehatan, Kementerian Kesehatan Republik Indonesia Pusat Pendidikan Sumber Daya Manusia Kesehatan Badan Pengembangan dan Pemberdayaan Sumber Daya Manusia Kesehatan*.
- Matovina, M. *et al.* (2021) 'An outbreak of ertapenem-resistant, carbapenemase-negative and porin-deficient ESBL-producing klebsiella pneumoniae complex', *Germs*, 11(2), pp. 199–210. doi: 10.18683/germs.2021.1257.
- Meatherall, B. L. *et al.* (2009) 'Incidence, Risk Factors, and Outcomes of Klebsiella pneumoniae Bacteremia', *American Journal of Medicine*, 122(9), pp. 866–873. doi: 10.1016/j.amjmed.2009.03.034.
- Mehrad, B. *et al.* (2015) 'Antimicrobial resistance in hospital-acquired gram-negative bacterial infections', *Chest*, 147(5), pp. 1413–1421. doi: 10.1378/chest.14-2171.
- Melzer, M., Petersen, I. and Cheasty, T. (2008) 'The difference in serotypes between extended- β -lactamase (ESBL) and non-ESBL-producing *E. coli* blood culture isolates at a UK district general hospital', *Journal of Hospital Infection*, 68(4), pp. 367–369. doi: 10.1016/j.jhin.2008.01.006.
- Mi, Z. *et al.* (2020) 'Improved Production of Pyrroloquinoline Quinone by Simultaneous Augmentation of Its Synthesis Gene Expression and Glucose Metabolism in *Klebsiella pneumoniae*', *Current Microbiology*, 77(7), pp. 1174–1183. doi: 10.1007/s00284-020-01918-3.
- Millanao, A. R. *et al.* (2021) *Biological Effects of Quinolones: A Family of Broad-Spectrum Antimicrobial Agents*.
- Miquel, S. *et al.* (2016) 'Anti-biofilm activity as a health issue', *Frontiers in Microbiology*, 7(APR), pp. 1–14. doi: 10.3389/fmicb.2016.00592.
- Mirzaii, M. *et al.* (2018) 'Determination of *gyrA* and *parC* mutations and prevalence of plasmid-mediated quinolone resistance genes in *Escherichia coli* and *Klebsiella pneumoniae* isolated from patients with urinary tract infection in Iran', *Journal of Global Antimicrobial Resistance*, 13, pp. 197–200. doi: 10.1016/j.jgar.2018.04.017.
- Mitscher, L. A. (2005) 'Bacterial topoisomerase inhibitors: Quinolone and pyridone antibacterial agents', *Chemical Reviews*, 105(2), pp. 559–592. doi: 10.1021/cr030101q.
- Mohammed, M. A. *et al.* (2021) 'Impact of target site mutations and plasmid associated resistance genes acquisition on resistance of *Acinetobacter baumannii* to fluoroquinolones', *Scientific Reports*, 11(1), pp. 1–16. doi: 10.1038/s41598-021-99230-y.
- Moradigaravand, D. *et al.* (2017) 'Evolution and epidemiology of multidrug-resistant *Klebsiella pneumoniae* in the United Kingdom and Ireland', *mBio*, 8(1), pp. 1–13. doi: 10.1128/mBio.01976-16.
- Mostafavi, M. *et al.* (2018) 'Interplay of *Klebsiella pneumoniae* *fabZ* and *lpxC* Mutations Leads to LpxC Inhibitor-Dependent Growth Resulting from Loss

- of Membrane Homeostasis', *mSphere*, 3(5), pp. 1–15. doi: 10.1128/msphere.00508-18.
- Motta, S. S., Cluzel, P. and Aldana, M. (2015) 'Adaptive resistance in bacteria requires epigenetic inheritance, genetic noise, and cost of efflux pumps', *PLoS ONE*, 10(3), pp. 3–8. doi: 10.1371/journal.pone.0118464.
- Moya, C. and Maicas, S. (2020) 'Antimicrobial Resistance in *Klebsiella pneumoniae* Strains: Mechanisms and Outbreaks', p. 11. doi: 10.3390/proceedings2020066011.
- Murphy, C. N. and Clegg, S. (2012) '*Klebsiella pneumoniae* and type 3 fimbriae: nosocomial infection, regulation and biofilm formation', *Future Microbiology*, 7(8), pp. 991–1002.
- Murray, P. R. and Masur, H. (2012) 'Current approaches to the diagnosis of bacterial and fungal bloodstream infections in the intensive care unit', *Critical Care Medicine*, 40(12), pp. 3277–3282. doi: 10.1097/CCM.0b013e318270e771.
- Nahar, P. *et al.* (2020) 'What contributes to inappropriate antibiotic dispensing among qualified and unqualified healthcare providers in Bangladesh? A qualitative study', *BMC Health Services Research*, 20(1), pp. 1–11. doi: 10.1186/s12913-020-05512-y.
- Nathwani, D., Tillotson, G. and Davey, P. (1997) 'Sequential antimicrobial therapy - The role of quinolones', *Journal of Antimicrobial Chemotherapy*, 39(4), pp. 441–446. doi: 10.1093/jac/39.4.441.
- Navon-Venezia, S., Kondratyeva, K. and Carattoli, A. (2017) '*Klebsiella pneumoniae*: A major worldwide source and shuttle for antibiotic resistance', *FEMS Microbiology Reviews*, 41(3), pp. 252–275. doi: 10.1093/femsre/fux013.
- Nirwati, H. *et al.* (2019) 'Biofilm formation and antibiotic resistance of *Klebsiella pneumoniae* isolated from clinical samples in a tertiary care hospital, Klaten, Indonesia', *BMC Proceedings*, 13(Suppl 11), pp. 1–8. doi: 10.1186/s12919-019-0176-7.
- Nisar, S., Kirkpatrick, L. D. and Shupp, J. W. (2021) 'Bacterial Virulence Factors and Their Contribution to Pathophysiology after Thermal Injury', *Surgical Infections*, 22(1), pp. 69–76. doi: 10.1089/sur.2020.188.
- Nowak, K. P. *et al.* (2021) 'Molecular and functional characterization of mobk protein—a novel-type relaxase involved in mobilization for conjugational transfer of *klebsiella pneumoniae* plasmid pigrk', *International Journal of Molecular Sciences*, 22(10). doi: 10.3390/ijms22105152.
- Opoku-Temeng, C., Kobayashi, S. D. and DeLeo, F. R. (2019) '*Klebsiella pneumoniae* capsule polysaccharide as a target for therapeutics and vaccines', *Computational and Structural Biotechnology Journal*, 17, pp. 1360–1366. doi: 10.1016/j.csbj.2019.09.011.
- Osagie, R. *et al.* (2017) 'Antibiotic susceptibility profile of *Klebsiella pneumoniae* isolated from sputum samples amongst hospitalized adults in parts of Edo State, South-South, Nigeria', *Merit Research Journal of Medicine and Medical Sciences*, 5(8), pp. 378–383.
- Osman, E. A. *et al.* (2020) 'Comparing conventional, biochemical and genotypic

- methods for accurate identification of *Klebsiella pneumoniae* in Sudan', *Access Microbiology*, 2(3), pp. 2–5. doi: 10.1099/acmi.0.000096.
- Pacios, O. *et al.* (2022) 'Adaptation of clinical isolates of *Klebsiella pneumoniae* to the combination of niclosamide with the efflux pump inhibitor phenyl-arginine- β -naphthylamide (Pa β N): co-resistance to antimicrobials', *Journal of Antimicrobial Chemotherapy*, 77(5), pp. 1272–1281. doi: 10.1093/jac/dkac044.
- Paczosa, M. K. (2016) 'Klebsiella pneumoniae : Going on the Offense with a Strong Defense', *Microbiology and Molecular Biology Reviews*, 80(3), pp. 629–661. doi: 10.1128/MMBR.00078-15.Address.
- Paczosa, M. K. and Meccas, J. (2016) 'Klebsiella pneumoniae: Going on the Offense with a Strong Defense', *Microbiology and Molecular Biology Reviews*, 80(3), pp. 629–661. doi: 10.1128/mmbr.00078-15.
- Palmeiro, J. K. *et al.* (2019) 'Molecular Epidemiology of Multidrug-Resistant *Klebsiella pneumoniae* Isolates in a Brazilian Tertiary Hospital', *Frontiers in Microbiology*, 10(July), pp. 1–11. doi: 10.3389/fmicb.2019.01669.
- Paluch, E. *et al.* (2020) 'Prevention of biofilm formation by quorum quenching', *Applied Microbiology and Biotechnology*, 104(5), pp. 1871–1881. doi: 10.1007/s00253-020-10349-w.
- Papagiannitsis, C. C. *et al.* (2013) 'OmpK35 and OmpK36 porin variants associated with specific sequence types of *Klebsiella pneumoniae*', *Journal of Chemotherapy*, 25(4), pp. 250–254. doi: 10.1179/1973947813Y.0000000075.
- Patel, J. . *et al.* (2015) *M100-S11, Performance standards for antimicrobial susceptibility testing*, *Clinical Microbiology Newsletter*. doi: 10.1016/s0196-4399(01)88009-0.
- Patel Singh, S. *et al.* (2021) 'Epidemiology, Antimicrobial susceptibility patterns and outcomes of bacteremia in an Apex trauma center of a tertiary health care institute with special reference to Methicillin Re...', *International Journal of Medical Science and Current Research*, 4(2), pp. 435–443.
- Patilaya, P., Husori, D. I. and Marhafanny, L. (2019) 'Susceptibility of klebsiella pneumoniae isolated from pus specimens of post-surgery patients in Medan, Indonesia to selected antibiotics', *Open Access Macedonian Journal of Medical Sciences*, 7(22), pp. 3861–3864. doi: 10.3889/oamjms.2019.520.
- Pham, T. D. M., Ziora, Z. M. and Blaskovich, M. A. T. (2019) 'Quinolone antibiotics', *MedChemComm*, 10(10), pp. 1719–1739. doi: 10.1039/c9md00120d.
- Phan, H. T. T. *et al.* (2018) 'Illumina short-read and MinION long-read WGS to characterize the molecular epidemiology of an NDM-1 *Serratia marcescens* outbreak in Romania', *Journal of Antimicrobial Chemotherapy*, 73(3), pp. 672–679. doi: 10.1093/jac/dkx456.
- Piekarska, K. *et al.* (2015) 'Co-existence of plasmid-mediated quinolone resistance determinants and mutations in *gyrA* and *parC* among fluoroquinolone-resistant clinical Enterobacteriaceae isolated in a tertiary hospital in Warsaw, Poland', *International Journal of Antimicrobial Agents*, 45(3), pp. 238–243. doi: 10.1016/j.ijantimicag.2014.09.019.

- Pilla, G., McVicker, G. and Tang, C. M. (2017) 'Genetic plasticity of the *Shigella* virulence plasmid is mediated by intra- and inter-molecular events between insertion sequences', *PLoS Genetics*, 13(9), pp. 1–19. doi: 10.1371/journal.pgen.1007014.
- Prajapati, J. D., Kleinekath, U. and Winterhalter, M. (2021) 'How to Enter a Bacterium: Bacterial Porins and the Permeation of Antibiotics'. doi: 10.1021/acs.chemrev.0c01213.
- Pu, Y., Ke, Y. and Bai, F. (2017) 'Active efflux in dormant bacterial cells – New insights into antibiotic persistence', *Drug Resistance Updates*, 30, pp. 7–14. doi: 10.1016/j.drug.2016.11.002.
- Qin, X. *et al.* (2020) 'The colonization of carbapenem-resistant *Klebsiella pneumoniae*: epidemiology, resistance mechanisms, and risk factors in patients admitted to intensive care units in China', *Journal of Infectious Diseases*, 221(Suppl 2), pp. S206–S214. doi: 10.1093/INFDIS/JIZ622.
- Radji, M., Fauziah, S. and Aribinuko, N. (2011) 'Antibiotic sensitivity pattern of bacterial pathogens in the intensive care unit of Fatmawati Hospital, Indonesia', *Asian Pacific Journal of Tropical Biomedicine*, 1(1), pp. 39–42. doi: 10.1016/S2221-1691(11)60065-8.
- Ravi, A. *et al.* (2019) 'Loss of microbial diversity and pathogen domination of the gut microbiota in critically ill patients', *Microbial Genomics*, 5(9). doi: 10.1099/mgen.0.000293.
- Raymundo, L. J. *et al.* (2008) *Coral Disease Handbook Guidelines for Assessment, Management*.
- Richard, G. A. *et al.* (2002) 'Single-dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women: Results from a randomized, double-blind, multicenter trial comparing single-dose to 3-day fluoroquinolone regimens', *Urology*, 59(3), pp. 334–339. doi: 10.1016/S0090-4295(01)01562-X.
- Rosas, N. C. and Lithgow, T. (2021) 'Targeting bacterial outer-membrane remodelling to impact antimicrobial drug resistance', *Trends in Microbiology*, xx(xx), pp. 1–9. doi: 10.1016/j.tim.2021.11.002.
- RSUD Prof. Dr. Margono Soekarjo (no date a) *Data Pasien Kasus Infeksi Klebsiella pneumoniae Di RSUD Prof. Dr. Margono Soekarjo Purwokerto Tahun 2019-2021*.
- RSUD Prof. Dr. Margono Soekarjo (no date b) *Pemerintah Provinsi Jawa Tengah RSUD Prof. Dr. Margono Soekarjo, 2014*. Available at: <https://www.rsmargono.go.id/> (Accessed: 6 June 2022).
- Ruggiu, F. *et al.* (2019) 'Size Matters and How You Measure It: A Gram-Negative Antibacterial Example Exceeding Typical Molecular Weight Limits', *ACS Infectious Diseases*, 5(10), pp. 1688–1692. doi: 10.1021/acsinfecdis.9b00256.
- Ruiz, J. (2003) 'Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection', (April), pp. 1109–1117. doi: 10.1093/jac/dkg222.
- Russo, T. A. and Marr, C. M. (2019) 'Hypervirulent *Klebsiella pneumoniae* Thomas', 25.

- Saha, S. *et al.* (2018) 'Biofilm production and its correlation with antibiotic resistance pattern among clinical isolates of *Pseudomonas aeruginosa* in a tertiary care hospital in north-east India', *International Journal of Advances in Medicine*, 5(4), p. 964. doi: 10.18203/2349-3933.ijam20183129.
- Saharman, Y. R. *et al.* (2020) 'Clinical impact of endemic NDM-producing *Klebsiella pneumoniae* in intensive care units of the national referral hospital in Jakarta, Indonesia', *Antimicrobial Resistance and Infection Control*, 9(1), pp. 1–14. doi: 10.1186/s13756-020-00716-7.
- Sahoo, A. *et al.* (2021) 'Antimicrobial Peptides Derived From Insects Offer a Novel Therapeutic Option to Combat Biofilm: A Review', *Frontiers in Microbiology*, 12(June). doi: 10.3389/fmicb.2021.661195.
- Samia, B. *et al.* (2013) 'Evaluation of biofilm formation of *Klebsiella pneumoniae* isolated from medical devices at the University Hospital of Tlemcen, Algeria', *African Journal of Microbiology Research*, 7(49), pp. 5558–5564. doi: 10.5897/ajmr12.2331.
- Schacht, P. *et al.* (1988) 'Worldwide clinical data on efficacy and safety of ciprofloxacin', *Infection*, 16(1 Supplement), pp. 29–43. doi: 10.1007/BF01650504.
- Schmidt, B. H. *et al.* (2010) 'A novel and unified two-metal mechanism for DNA cleavage by type II and IA topoisomerases', *HHS Public Access Nature*, 465(7298), pp. 641–644. doi: 10.1038/nature08974.A.
- Schneiders, T., Amyes, S. G. B. and Levy, S. B. (2003) 'Role of AcrR and RamA in fluoroquinolone resistance in clinical *Klebsiella pneumoniae* isolates from Singapore', *Antimicrobial Agents and Chemotherapy*, 47(9), pp. 2831–2837. doi: 10.1128/AAC.47.9.2831-2837.2003.
- Segev, S. *et al.* (1999) 'Safety of long-term therapy with ciprofloxacin: Data analysis of controlled clinical trials and review', *Clinical Infectious Diseases*, 28(2), pp. 299–308. doi: 10.1086/515132.
- Shakib, P. *et al.* (2012) 'Prevalence of OmpK35 and OmpK36 porin expression in beta-lactamase and non-beta-lactamase-producing *Klebsiella pneumoniae*', *Biologics: Targets and Therapy*, 6, pp. 1–4. doi: 10.2147/btt.s27582.
- Shilpa, K., Thomas, R. and Ramyashree, A. (2015) 'Isolation and Antimicrobial sensitivity pattern of *Klebsiella pneumoniae* from sputum samples in a tertiary care hospital', *International Journal of Biomedical and Advance Research IJBAR International Journal of Biomedical and Advance Research Journal*, 6(605), pp. 427–430. doi: 10.7439/ijbar.
- Shokoozadeh, L. *et al.* (2019) 'Mutations in *gyrA* and *parC* genes in quinolone-resistant *Klebsiella pneumoniae* isolates from borujerd hospitals', *Journal of Advances in Medical and Biomedical Research*, 27(120), pp. 1–7. doi: 10.30699/jambs.27.120.1.
- Sick, A. C. *et al.* (2014) 'Empiric combination therapy for gram-negative bacteremia', *Pediatrics*, 133(5). doi: 10.1542/peds.2013-3363.
- Silver, L. L. (2016) 'A Gestalt approach to Gram-negative entry', *Bioorganic and Medicinal Chemistry*, 24(24), pp. 6379–6389. doi: 10.1016/j.bmc.2016.06.044.

- Siswandari, W. *et al.* (2018) 'PROFIL BAKTERI PENYEBAB SEPSIS DI RUANG PERAWATAN INTENSIVE RSUD PROF . DR . MARGONO SOEKARJO PURWOKERTO Wahyu Siswandari , Rani Afifah Nur Hestiyani , Vitasari Indriani , I Dewa Sang Ayu Putu Peramiarti Fakultas', *Prosiding Seminar Nasional Pengembangan Sumber Daya Perdesaan dan Kearifan Lokal Berkelanjutan VIII*, 1(November), pp. 14–15.
- Smith, A. C. and Hussey, M. A. (2005) 'Gram stain protocols', *American Society for Microbiology*, 1(September 2005), p. 14.
- Sriram, D. *et al.* (2007) 'Newer tetracycline derivatives: Synthesis, anti-HIV, antimycobacterial activities and inhibition of HIV-1 integrase', *Bioorganic and Medicinal Chemistry Letters*, 17(8), pp. 2372–2375. doi: 10.1016/j.bmcl.2006.11.055.
- Starzyk-Luszcz, K. *et al.* (2017) 'Mortality due to nosocomial infection with *Klebsiella pneumoniae* ESBL+', *Advances in Experimental Medicine and Biology*, 1022, pp. 19–26. doi: 10.1007/5584_2017_38.
- Su, L. X. *et al.* (2019) 'Infection management strategy based on prevention and control of nosocomial infections in intensive care units', *Chinese Medical Journal*, 132(1), pp. 115–119. doi: 10.1097/CM9.000000000000029.
- Sugawara, E., Kojima, S. and Nikaido, H. (2016) 'Klebsiella pneumoniae Major Porins OmpK35 and OmpK36 Allow More Efficient Diffusion of Beta-Lactams than Their *Escherichia coli* Homologs OmpF dan OmpC', *Journal of Bacteriology*, 198(23), pp. 3200–3208. doi: 10.1128/JB.00590-16.Editor.
- Sugianli, A. K. *et al.* (2020) 'Laboratory-based versus population-based surveillance of antimicrobial resistance to inform empirical treatment for suspected urinary tract infection in Indonesia', *PLoS ONE*, 15(3), pp. 1–10. doi: 10.1371/journal.pone.0230489.
- Surgers, L. *et al.* (2019) 'Biofilm formation by ESBL-producing strains of *Escherichia coli* and *Klebsiella pneumoniae*', *International Journal of Medical Microbiology*, 309(1), pp. 13–18. doi: 10.1016/j.ijmm.2018.10.008.
- Svane, S. *et al.* (2020) 'Inhibition of urease activity by different compounds provides insight into the modulation and association of bacterial nickel import and ureolysis', *Scientific Reports*, 10(1), pp. 1–14. doi: 10.1038/s41598-020-65107-9.
- Szabo, O. *et al.* (2018) 'Contribution of OqxAB efflux pump in selection of fluoroquinolone-resistant *klebsiella pneumoniae*', *Canadian Journal of Infectious Diseases and Medical Microbiology*, 2018. doi: 10.1155/2018/4271638.
- Tamma, P. D., Cosgrove, S. E. and Maragakis, L. L. (2012) 'Combination therapy for treatment of infections with gram-negative bacteria', *Clinical Microbiology Reviews*, 25(3), pp. 450–470. doi: 10.1128/CMR.05041-11.
- Tang, M. *et al.* (2020) 'The role and relationship with efflux pump of biofilm formation in *Klebsiella pneumoniae*', *Microbial Pathogenesis*, 147, p. 104244. doi: 10.1016/j.micpath.2020.104244.
- Tängdén, T. (2014) 'Combination antibiotic therapy for multidrug-resistant Gram-negative bacteria', *Upsala Journal of Medical Sciences*, 119(2), pp. 149–153.

doi: 10.3109/03009734.2014.899279.

- Terp, D. K. and Rybak, M. (1987) 'Ciprofloxacin', *Drug Intelligence and Clinical Pharmacy*, 21, pp. 568–574.
- Tiwari, S. K. *et al.* (2021) 'Starvation Survival and Biofilm Formation under Subminimum Inhibitory Concentration of QAMs', *BioMed Research International*, 2021. doi: 10.1155/2021/8461245.
- Unlu, O. *et al.* (2018) 'Epidemic *Klebsiella pneumoniae* ST258 incidence in ICU patients admitted to a university hospital in Istanbul'. doi: 10.3855/jidc.13430.
- Unlu, O. *et al.* (2021) 'Epidemic *Klebsiella pneumoniae* ST258 incidence in ICU patients admitted to a university hospital in Istanbul', *Journal of Infection in Developing Countries*, 15(5), pp. 665–671. doi: 10.3855/JIDC.13430.
- Usai, D. *et al.* (2019) 'Brief Original Article Enhancement of antimicrobial activity of pump inhibitors associating drugs', *The Journal of Infection in Developing Countries*, 13(2), pp. 162–164. doi: 10.3855/jidc.11102.
- Versporten, A. *et al.* (2018) 'Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey', *The Lancet Global Health*, 6(6), pp. e619–e629. doi: 10.1016/S2214-109X(18)30186-4.
- Villa, L. *et al.* (2014) 'Genomics of KPC-producing *Klebsiella pneumoniae* sequence type 512 clone highlights the role of RamR and ribosomal S10 protein mutations in conferring tigecycline resistance', *Antimicrobial Agents and Chemotherapy*, 58(3), pp. 1707–1712. doi: 10.1128/AAC.01803-13.
- Vincent, J. L. *et al.* (2020) 'Prevalence and Outcomes of Infection among Patients in Intensive Care Units in 2017', *JAMA - Journal of the American Medical Association*, 323(15), pp. 1478–1487. doi: 10.1001/jama.2020.2717.
- Viveiros, M. *et al.* (2008) 'New Methods for the Identification of Efflux Mediated MDR Bacteria, Genetic Assessment of Regulators and Efflux Pump Constituents, Characterization of Efflux Systems and Screening for Inhibitors of Efflux Pumps', *Current Drug Targets*, 9(9), pp. 760–778. doi: 10.2174/138945008785747734.
- Vuotto, C. *et al.* (2017) 'Biofilm formation and antibiotic resistance in *Klebsiella pneumoniae* urinary strains', *Journal of Applied Microbiology*, 123(4), pp. 1003–1018. doi: 10.1111/jam.13533.
- Walaszek, M. *et al.* (2018) 'Epidemiology of Ventilator-Associated Pneumonia, microbiological diagnostics and the length of antimicrobial treatment in the Polish Intensive Care Units in the years 2013-2015', *BMC Infectious Diseases*, 18(308), pp. 1–9.
- Walker, S. S. and Black, T. A. (2021) 'Are outer-membrane targets the solution for MDR Gram-negative bacteria?', *Drug Discovery Today*, 26(9), pp. 2152–2158. doi: 10.1016/j.drudis.2021.03.027.
- Walters III, M. C. *et al.* (2003) 'Contributions of Antibiotic Penetration, Oxygen Limitation', *Antimicrobial Agents and Chemotherapy*, 47(1), pp. 317–323. doi: 10.1128/AAC.47.1.317.

- Wang, C. *et al.* (2019) 'Epidemiologic analysis and control strategy of klebsiella pneumoniae infection in intensive care units in a teaching hospital of People's Republic of China', *Infection and Drug Resistance*, 12, pp. 391–398. doi: 10.2147/IDR.S189154.
- Wang, G. *et al.* (2020) 'The characteristic of virulence, biofilm and antibiotic resistance of klebsiella pneumoniae', *International Journal of Environmental Research and Public Health*, 17(17), pp. 1–17. doi: 10.3390/ijerph17176278.
- Wang, J. *et al.* (2020) *Electrophysiological Characterization of Transport Across Outer-Membrane Channels from Gram-Negative Bacteria in Presence of Lipopolysaccharides*. German. doi: doi.org/10.1002/anie.201913618.
- Wassef, M. *et al.* (2015) 'The role of OmpK35, OmpK36 porins, and production of β -lactamases on imipenem susceptibility in klebsiella pneumoniae clinical isolates, Cairo, Egypt', *Microbial Drug Resistance*, 21(6), pp. 577–580. doi: 10.1089/mdr.2014.0226.
- Wentzell, L. M. and Maxwell, A. (2000) 'The complex of DNA gyrase and quinolone drugs on DNA forms a barrier to the T7 DNA polymerase replication complex', *Journal of Molecular Biology*, 304(5), pp. 779–791. doi: 10.1006/jmbi.2000.4266.
- WHO (2019) *Critically Important Antimicrobials for Human Medicine*. 6th revisi. World Health Organization.
- Windels, E. M. *et al.* (2019) 'Antibiotics: Combatting tolerance to stop resistance', *mBio*, 10(5). doi: 10.1128/mBio.02095-19.
- Winterhalter, M. (2021) 'Antibiotic uptake through porins located in the outer membrane of Gram-negative bacteria', *Expert Opinion on Drug Delivery*, 18(4), pp. 449–457. doi: 10.1080/17425247.2021.1847080.
- World Health Organization (WHO) (2020) *GLASS Report: Early Implementation 2020*.
- Wyres, K. L. *et al.* (2019) 'Distinct evolutionary dynamics of horizontal gene transfer in drug resistant and virulent clones of Klebsiella pneumoniae', *PLoS Genetics*, 15(4), pp. 1–25. doi: 10.1371/journal.pgen.1008114.
- Wyres, K. L. and Holt, K. E. (2018) 'Klebsiella pneumoniae as a key trafficker of drug resistance genes from environmental to clinically important bacteria', *Current Opinion in Microbiology*, 45, pp. 131–139. doi: 10.1016/j.mib.2018.04.004.
- Wyres, K. L., Lam, M. M. C. and Holt, K. E. (2020) 'Population genomics of Klebsiella pneumoniae', *Nature Reviews Microbiology*, 18(6), pp. 344–359. doi: 10.1038/s41579-019-0315-1.
- Xu, Z. *et al.* (2017) 'Recent advances of pyrazole-containing derivatives as anti-tubercular agents', *European Journal of Medicinal Chemistry*, 139, pp. 429–440. doi: 10.1016/j.ejmech.2017.07.059.
- Yamasaki, S. *et al.* (2021) 'Genetic analysis of ESBL-producing Klebsiella pneumoniae isolated from UTI patients in Indonesia', *Journal of Infection and Chemotherapy*, 27(1), pp. 55–61. doi: 10.1016/j.jiac.2020.08.007.
- Yang, L. *et al.* (2007) 'Effects of iron on DNA release and biofilm development by

- Pseudomonas aeruginosa*', *Microbiology*, 153(5), pp. 1318–1328. doi: 10.1099/mic.0.2006/004911-0.
- Yang, S. *et al.* (2021) 'Bacterial and fungal co-infections among COVID-19 patients in intensive care unit', *Microbes and Infection*, 23(4–5), p. 104806. doi: 10.1016/j.micinf.2021.104806.
- Zechiedrich, E. L. *et al.* (2000) 'Roles of topoisomerases in maintaining steady-state DNA supercoiling in *Escherichia coli*', *Journal of Biological Chemistry*, 275(11), pp. 8103–8113. doi: 10.1074/jbc.275.11.8103.
- Zgurskaya, H. I. and Nikaido, H. (2000) 'MicroReview Multidrug resistance mechanisms: drug efflux across two membranes', 37.
- Zhang, G. *et al.* (2018) 'European Journal of Medicinal Chemistry Ciprofl oxacin derivatives and their antibacterial activities', *European Journal of Medicinal Chemistry*, 146, pp. 599–612. doi: 10.1016/j.ejmech.2018.01.078.
- Zhang, L. *et al.* (2015) 'Design and biological evaluation of novel quinolone-based metronidazole derivatives as potent Cu²⁺ mediated DNA-targeting antibacterial agents', *Bioorganic and Medicinal Chemistry Letters*, 25(17), pp. 3699–3705. doi: 10.1016/j.bmcl.2015.06.041.
- Zhang, Y. *et al.* (2015) 'Emergence of a hypervirulent carbapenem-resistant *Klebsiella pneumoniae* isolate from clinical infections in China', *Journal of Infection*, 71(5), pp. 553–560. doi: 10.1016/j.jinf.2015.07.010.
- Zheng, J. X. *et al.* (2018) 'Biofilm formation in *Klebsiella pneumoniae* bacteremia strains was found to be associated with CC23 and the presence of wcaG', *Frontiers in Cellular and Infection Microbiology*, 8(FEB). doi: 10.3389/fcimb.2018.00021.
- Zhong, H. Q. *et al.* (2013) 'Influence of induced ciprofloxacin resistance on efflux pump activity of *Klebsiella pneumoniae*', *Journal of Zhejiang University: Science B*, 14(9), pp. 837–843. doi: 10.1631/jzus.B1200221.
- Zhou, G. *et al.* (2015) 'The three bacterial lines of defense against antimicrobial agents', *International Journal of Molecular Sciences*, 16(9), pp. 21711–21733. doi: 10.3390/ijms160921711.
- Zhou, X. Y. *et al.* (2016) 'In vitro characterization and inhibition of the interaction between ciprofloxacin and berberine against multidrug-resistant *Klebsiella pneumoniae*', *Journal of Antibiotics*, 69(10), pp. 741–746. doi: 10.1038/ja.2016.15.
- Zlatian, O. *et al.* (2018) 'Antimicrobial resistance in bacterial pathogens among hospitalised patients with severe invasive infections', *Experimental and Therapeutic Medicine*, 16(6), pp. 4499–4510. doi: 10.3892/etm.2018.6737.